Bio-Techne Corp (TECH) FinancialsTECHFinancialBio-Techne Corp

Bio-Techne Corporation (TECH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 82.6% of total sales, equivalent to $257.34M. Other significant revenue streams include Instruments and Service. Understanding this composition is critical for investors evaluating how TECH navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Bio-Techne Corporation maintains a gross margin of 67.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 25.74%, while the net margin is 16.39%. These profitability ratios, combined with a Return on Equity (ROE) of 5.34%, provide a clear picture of how effectively TECH converts its operational activities into shareholder value.

In the context of the broader market, TECH competes directly with industry leaders such as SMMT and HALO. With a market capitalization of $11.28B, it holds a significant position in the sector. When comparing efficiency, TECH's gross margin of 67.25% stands against SMMT's N/A and HALO's 77.40%. Such benchmarking helps identify whether Bio-Techne Corporation is trading at a premium or discount relative to its financial performance.

Bio-Techne's recent financial performance shows a recovery with Q4 FY2026 net profit of $54.622 million, up from a loss of $17.677 million in the previous year. The gross margin is strong at 67.25%, indicating effective cost management and profitability.